- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
PMV Pharmaceuticals Projected to Post Quarterly Earnings
The biotech company is expected to announce Q4 2025 results on Monday, March 2nd.
Mar. 3, 2026 at 2:15am
Got story updates? Submit your updates here. ›
PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company focused on developing therapies for p53 mutations in cancer, is expected to issue its Q4 2025 financial results before the market opens on Monday, March 2nd. Analysts forecast the company will report earnings of ($0.40) per share for the quarter.
Why it matters
PMV Pharmaceuticals is a closely watched biotech company developing novel cancer treatments, so its quarterly earnings reports provide important updates on the progress of its lead drug candidate PC14586 and the overall financial health of the business.
The details
PMV Pharmaceuticals is scheduled to host a conference call to discuss the Q4 2025 results on Friday, March 6, 2026 at 9:30 AM ET. The company's stock opened at $1.70 per share on the previous trading day and has a 52-week range of $0.81 to $1.84.
- PMV Pharmaceuticals will report Q4 2025 earnings on Monday, March 2, 2026.
- The company will host an earnings call on Friday, March 6, 2026 at 9:30 AM ET.
The players
PMV Pharmaceuticals
A precision oncology company engaged in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586.
What’s next
Investors will be closely watching PMV Pharmaceuticals' Q4 2025 earnings report and conference call for updates on the progress of its pipeline and any guidance on future milestones.
The takeaway
As a biotech company focused on developing innovative cancer treatments, PMV Pharmaceuticals' quarterly financial performance and pipeline updates are closely monitored by investors and the broader healthcare industry.
